Trials / Withdrawn
WithdrawnNCT04398290
iNOPulse for COVID-19
Randomized Controlled Trial Of A Delivered Continuously By Nasal Cannula For The Treatment Of Patients With COVID-19 And Mild To Moderate Hypoxemia Requiring Supplemental Oxygen
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Roger Alvarez · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This randomized, controlled trial will assess the efficacy and safety of pulsed iNO in subjects with COVID-19 who are hospitalized and require supplemental oxygen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inhaled nitric oxide (iNO) | iNO Pulse 250 mcg/kg ideal body weight (IBW)/hour |
| DRUG | Nitrogen gas | 250 mcg/kg ideal body weight (IBW)/hour |
| DRUG | Oxygen gas | Supplemental oxygen administered via nasal cannula |
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2021-06-01
- Completion
- 2021-07-15
- First posted
- 2020-05-21
- Last updated
- 2020-08-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04398290. Inclusion in this directory is not an endorsement.